












hev Port Pneumol. 2014;20(4):200--207
www.revportpneumol.org
RIGINAL ARTICLE
RCC1  expression  correlated  with EGFR  and
linicopathological variables  in patients  with non-small
ell lung cancer.  An  immunocytochemical  study  on
ne-needle aspiration  biopsies  samples
. Kalogerakia,∗, I. Karvela-Kalogerakia, D. Tamiolakisa, P. Petrakia,
.  Saridakib, M. Tzardia
Department  of  Pathology-Cytopathology,  Medical  School  University  of  Crete,  Crete,  Greece
Department  of  Oncology,  Medical  School  University  of  Crete,  Crete,  Greece
eceived  17  June  2013;  accepted  15  November  2013







Purpose:  Expression  of  ERCC1  has  not  been  well  described  in  ﬁne-needle  aspiration  biopsies
(FNABs) in  patients  with  non-small  cell  lung  cancer  (NSCLC).  We  investigated  the  expression
of ERCC1  in  correlation  with  EGFR  expression  and  clinicopathological  factors  in  patients  with
NSCLC in  order  to  determine  if  these  play  a  role  in  the  prognosis  of  the  disease.
Methods:  We  studied  45  patients,  34  with  adenocarcinoma  and  11  with  squamous  cell  carci-
noma. Of  these  45  patients,  35  were  males  and  10  females,  aged  between  45  and  83  years,
30 smokers  and  15  non-smokers.  Eighteen  (18)  tumors  were  of  stage  I,  twelve  (12)  stage  II
and ﬁfteen  (15)  stage  III.  To  investigate  the  expression  of  ERCC1  and  EGFR  (scores  0,  1,  2,
3), immunocytochemistry  was  performed  on  air  dried  specimens  (FNABs)  using  monoclonal
antibodies  by  alkaline-phosphatase  (APAAP)  method.
Results:  ERCC1  expression  was  detected  in  tumors  from  27  patients  (60%)  and  EGFR  in  10
patients (22.2%).  ERCC1  was  expressed  more  frequently  in  males  (65.7%)  in  patients  >65  years
old (64%),  in  smokers  (66.7%)  and  in  stage  I  (66.7%).  Negative  ERCC1  expression  was  signiﬁcantly
associated  with  the  presence  of  EGFR.  EGFR  was  expressed  only  in  adenocarcinomas  and  more
frequently  in  women  (70%)  and  non  smokers  (53.3%).
Conclusions:  ERCC1  expression  was  identiﬁed  as  positive  (scores  2+  and  3+)  in  the  majority  of
NSCLCs and  seems  to  be  an  independent  prognostic  marker  of  longer  survival.  In  addition  EGFR
expression was  positive  (scores  2+  and  3+)  in  the  minority  of  NSCLCs  and  only  in  adenocarcino-
mas, more  frequently  in  ERCC1-negative  (scores  0  and  1+)  tumors,  suggesting  that  it  is  not  an
independent  prognostic  marker  for  the  outcome  of  the  patients  suffering  from  NSCLC.
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Expressão  ERCC1  Correlacionada  com  EGFR  e  Variáveis  Clinicopatológicas  em  Doentes
com  Carcinoma  Pulmonar  de  Não  Pequenas  Células.  Um  estudo  imunocitoquímico  em
amostras  biópsias  aspirativas  por  agulha  ﬁna
Resumo
Objetivo:  A  expressão  de  ERCC1  não  foi  ainda  suﬁcientemente  descrita  em  biópsias  aspirativas
por agulha  ﬁna  (FNAB)  em  doentes  com  carcinoma  pulmonar  de  não  pequenas  células  (NSCLC).
Investigámos  a  expressão  de  ERCC1  em  correlac¸ão  com  a  expressão  EGFR  e  os  fatores  clin-
icopatológicos  em  doentes  com  NSCLC  para  determinar  se  estes  desempenham  um  papel  no
prognóstico  da  doenc¸a.
Métodos:  Estudámos  45  doentes,  34  com  adenocarcinoma  e  11  com  carcinoma  de  células
escamosas.  Desses  45  doentes,  35  eram  homens  e  10  mulheres,  com  idades  entre  os  45-83
anos, 30  fumadores  e  15  não  fumadores.  Dezoito  tumores  encontravam-se  no  estádio  I,  12  no
estádio II  e  15  no  estádio  III.  Para  investigar  a  expressão  de  ERCC1  e  EGFR  (resultados  0,  1,  2,
3), foi  realizada  imunocitoquímica  em  espécimes  a  seco  (FNAB),  usando  anticorpos  monoclonais
pelo método  de  fosfatase  alcalina  (APAAP).
Resultados:  A  expressão  ERCC1  foi  detetada  em  tumores  de  27  doentes  (60%)  e  a  do  EGFR  em  10
doentes (22,2%).  O  ERCC1  foi  expresso  com  maior  frequência  em  homens  (65,7%),  em  doentes
com mais  de  65  anos  (64%),  em  fumadores  (66,7%)  e  no  estádio  I  (66,7%).  A  expressão  ERCC1
negativa  foi  signiﬁcativamente  associada  à  presenc¸a  de  EGFR.  O  EGFR  foi  expresso  apenas  em
adenocarcinomas  e  com  maior  frequência  em  mulheres  (70%)  e  não  fumadores  (53,3%).
Conclusões:  A  expressão  de  ERCC1  foi  identiﬁcada  como  positiva  (resultados  2+  e  3+)  na  maioria
dos NSCLC  e  parece  ser  um  marcador  de  prognóstico  independente  de  maior  sobrevivência.  Além
disso, a  expressão  de  EGFR  foi  positiva  (resultados  2+  e  3+)  numa  minoria  dos  NSCLCs  e  apenas
em adenocarcinomas,  com  maior  frequência  em  tumores  ERCC1-negativos  (resultados  0  e  1+),
sugerindo que  não  é  um  marcador  de  prognóstico  independente  na  evoluc¸ão  de  doentes  que
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Introduction
Primary  lung  cancer  is  the  leading  cause  of  cancer  death  in
many  countries.1,2 Approximately  80%  of  primary  lung  can-
cers  are  non  small-cell  lung  carcinomas  (NSCLCs).  Surgical
resection  is  considered  to  be  a  curative  treatment  during
earlier  stage  and  adjuvant  chemotherapy  or  radiotherapy  in
more  advanced  stage  of  the  disease.
Excision  repair  cross-complementation  group  1(ERCC1)  is
one  of  16  genes  that  encode  the  proteins  of  the  nucleotide
excision  in  repair  complex.3,4 This  multiprotein  complex  also
links  the  DNA  repair  process  with  other  cellular  processes
such  as  DNA  transcription.
Different  studies  have  already  reported  the  expression  of
ERCC1  in  human  ovarian  cancer  cells  in  vitro5 in  primary  gas-
tric  adenocarcinomas6 in  colorectal  cancer7 in  esophageal
cancer8 and  in  non  small  cell  lung  cancer  (NSCLC).9
Epidermal  growth  factor  (EGFR)  is  a  17  kDa  transmem-
brane  glycoprotein  which  can  bind  and  become  activated
by  various  ligands  including  epidermal  growth  factor  (EGF),
transforming  growth  factor  alpha  (TGFa)  and  certain  virally
encoded  growth  factors.  EGFR  overexpression  is  found  in
a  variety  of  neoplasms  such  as  malignant  gliomas,  breast
and  lung  carcinomas.  Among  lung  cancers,  overexpression  is
largely  due  to  increased  transcription  and  is  most  prevalent
in  lung  squamous  cell  carcinomas.  Increased  overexpression
has  also  been  observed  in  adenocarcinomas  of  the  lung  and
large  cell  carcinomas  but  not  in  small  cell  carcinomas.10
The  aim  of  this  work  is  to  clarify  and  validate,  in  a
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xpression  correlated  with  EGFR  expression  and  other  clin-
copathological  variables,  using  immunocytochemistry  in
ytological  material  (FNAB)  of  patients  with  non  small  cell
ung  cancers  (NSCLCs).
aterials and methods
orty-ﬁve  patients  (45)  with  operable  NSCLC  were  diagnosed
nd  studied  cytologically  on  FNABs  and  had  their  diagnoses
onﬁrmed  histologically  after  the  operation.  Diagnoses  were
stablished  by  both  morphology  and  immunocytochemistry.
bjective  and  measurable  cytomorphologic  differences
etween  squamous  cell  carcinoma  and  adenocarcinoma
xist.  The  aspirated  cancer  cells  in  adenocarcinoma  are
ound  in  clusters  or  singly.  The  cytoplasm  is  ﬁnely  vacuo-
ated  and  faintly  stained  with  indistinct  cell  borders.  The
uclei  have  a  delicate  chromatin  pattern  and  prominent
ucleoli.  In  contrast  tumor  cells  of  squamous  cell  carcinoma
ave  sharp  cell  borders,  dense  cytoplasm,  nuclear  hyper-
hromasia,  and  signiﬁcant  nuclear  membrane  irregularities.
pindle  cell  morphology  and  ‘‘tadpole’’  cells  are  commonly
een.  However  cytomorphologic  differences  between  the
wo  types  are  not  always  consistent.  Immunocytochemistry
as  a signiﬁcant  role  as  an  adjunct  study  in  this  con-
ext.  In  our  settings  we  performed  immunocytochemistry
n  cell  block  material  with  antibodies  against  TTF-1  (clone
G7G3/1,  Dako,  M3575),  CK7  (clone  OV-TL,  Dako,  M7018),
K20  (clone  K20.8,  Dako,  M7019),  P63  (clone  4A4,  Dako,
7247),  CK5/6  (clone  D5/16/B4,  Dako,  M7237),  with  the
ilutions  of  1:50,  1:200,  1:30,  1:60,  and  1:10  respectively.































































mmunostaining  was  performed  on  the  Ventana  automated
ystem.  Thyroid  tissue  was  used  as  the  control  for  TTF-1,
enign  lung  for  CK7,  colon  cancer  for  CK20,  benign  prostate
or  P63,  and  skin  for  CK5/6.  Immunostaining  was  evaluated
emi-quantitatively  for  both  extent  and  intensity  and  was
eﬁned  as  negative  if  no  staining  was  present,  low  if  stain-
ng  was  present  in  less  than  10%  of  tumor  cells,  moderate
f  staining  occurred  in  10--50%  of  tumor  cells,  and  high  if
taining  was  seen  in  >50%  of  tumor  cells.  Adenocarcino-
as  were  TTF-1  positive,  CK7  positive,  CK20  negative,  P63
egative,  and  CK5/6  negative.  Squamous  cell  carcinomas
ere  TTF-1  negative,  CK7  negative,  CK20  negative,  P63  posi-
ive,  and  CK5/6  positive.  In  all  positive  cases  the  expression
f  staining  was  strong  and  diffuse,  except  for  one  case  of
denocarcinoma  in  which  CK20  was  expressed  focally  and
oderately.  Of  these  tumors  34  were  adenocarcinomas,  11
ere  squamous  cell  carcinomas,  18  stage  I,  12  stage  II  and  15
tage  III.  Thirty-ﬁve  of  the  patients  (35)  received  adjuvant
hemotherapy.  Platinum  based  chemotherapy  was  adminis-
rated  (cisplatin)  combined  with  gemcitabine.  All  patients
eceived  the  same  medication.  For  the  cytological  diagno-
is  of  NSCLCs,  the  specimen  from  FNABs  was  stained  using
apanicolaou  and  Giemsa  stains.  Immunocytochemistry  was
erformed  on  air  dried  specimens  using  the  alkaline  phos-
hatase  (APAAP)  method.  To  estimate  the  ERCC1  expression
he  ERCC1  Ab-2  (clone  8F1)  IgG2b  isotype  mouse  monoclonal
ntibody  (Thermo  Scientiﬁc,  Fremont  CA,  USA)  was  used.
o  estimate  the  EGFR  expression  we  used  the  monoclonal
ouse  anti  human  epidermal  growth  factor  receptor  clone
11,  IgG1,  Kappa  isotype  (DAKO,  Carpinteria,  CA,  USA).  We
ound  that  a  dilution  of  1:200  with  an  1  h  incubation  in  a
icrowave  oven  750  W  for  3  cycles  was  optimal,  and  a  very
ight  hematoxylin  counterstain  was  performed  before  count-
ng.  For  ERCC1,  stromal  cells  surrounding  the  tumor  areas
erved  as  internal  positive  controls  and  for  EGFR  we  used
issue  from  breast  cancer  as  positive  control.  For  negative
ontrol  we  omitted  the  primary  antibody.
The  slides  were  examined  using  10×  ocular  lens  and  10
elds  per  slide  (at  least  1000  cells)  were  selected  randomly
nd  counted  using  an  40×  objective  lens.



















pigure  2  EGFR  expression  in  adenocarcinoma  grade  III  (EGFR
MMUNOSTAIN  400×).
ERCC1  expression  was  nuclear  (Fig.  1),  and  EGFR  trans-
embrane  (Fig.  2).  The  stain  intensity  was  scored  by  two
rained  cytopathologists  (AK  and  DT).  Each  cell  was  scored  as
,  1,  2,  3  which  corresponded  to  negative,  weak,  moderate
nd  strong  staining  intensities.  Percentages  of  stained  cells
ere  counted  and  a  ﬁnal  score  was  calculated  by  summing
he  products  of  staining  intensities  (0--3)  and  distributions
0--100%).The  scores  ranged  from  0  to  300  (percentage  of
ositive  cells  ×  staining  intensity),  and  the  median  score  was
sed  as  a  cut-off  criterion.  The  scores  0,  1  were  considered
s  negative  and  the  scores  2  and  3  as  positive.  Data  from
his  study  were  analyzed  with  the  Pearson’s  chi-square  test.
he  level  of  statistical  signiﬁcance  chosen  was  0.05.
In  cases  positive  for  EGFR,  mutational  proﬁle  was  not
tudied  as  this  was  beyond  the  purpose  of  our  work.
esults
atient  characteristics
his  study  included  45  patients  (35  males  and  10  females)
ith  a  median  age  of  63  years.  Thirty  (66.7%)  had  a  his-
ory  of  smoking.  Adenocarcinomas  accounted  for  75.5%  and
quamous  cell  carcinomas  25.5%.  Stages  I,II,  and  III  were
iagnosed  in  40%,  26.7%  and  33.3%  respectively.  Thirty  ﬁve
atients  (77.8%)  received  adjuvant  chemotherapy  (Table  1)
nd  the  median  survival  of  the  patients  was  ranged  between
.9  and  9  years.
RCC1  expression  by  immunocytochemistry
he  expression  of  ERCC1  was  evaluable  in  all  45  patients,
nd  the  median  score  was  10.
Patients  were  divided  into  2  groups  about  this  median
alue.  27  patients  had  ERCC-1  positive  tumors  and  a  score
10  and  18  had  ERCC-1  negative  tumors  and  a  score  of
 10.  ERCC-1  was  frequent  in  squamous  cell  carcinoma
81.8%  for  squamous  cell  carcinomas  versus  52.9%  for  adeno-
arcinomas,  p  <  0.001)  and  in  smokers  (66.7%  for  smokers
ersus  46.7%  for  non  smokers  p  =  0.029)  (Table  2).
GFR  expression  by  immunocytochemistryGFR  expression  was  found  in  10  patients  (22.2%).  The  fre-
uency  of  EGFR  expression  was  found  to  be  signiﬁcantly
elated  to  female  gender  (70%  for  females  vs.  8.6%  for  males,
 < 0.001),  smoking  history  (53.3%  for  non  smokers  vs.  6.6%
ERCC-1,  EGFR,  and  clinical  variables  in  NSCLC  
Table  1  Characteristics  of  patients  with  NSCLC.
Number  of  patients
Age  Median  63  years  (range  45--83)
Sex
Male  35  (77.8)
Female  10  (22.2)
Smoking  history
Smokers  30  (66.7)
Non  smokers  15  (33.3)
Tumor  stage
I 18  (40)
II 12  (26.7)
III 15  (33.3)
Cyto-histopathology
Adenocarcinoma  34  (75.5)
Squamous  cell  carcinoma  11  (25.5)
Adjuvant  chemotherapy



























mNo  10  (22.2)
for  smokers,  p  <  0.001).  EGFR  was  expressed  only  in  adeno-
carcinomas  (in  10  of  34  tumors,  29.4%).  No  expression  was
found  in  squamous  cell  carcinomas  (Table  3).
Correlations  between  survival,  ERCC1  and  EGFR
expressionPatients  with  positive  ERCC1  expression  survived  longer
(median  overall  survival  7.5  years  for  ERCC1  positive  vs.
3.8  years  for  ERCC-1  negative,  p  =  0.045).  EGFR  expression









Male  23  (65.7%)  
Female 4  (40%)  
Age
≤65 years  11  (55%)  
>65 years  16  (64%)  
Smoking status
Smokers  20  (66.7%)  
Non smokers  7  (46.7%)  
Cyto-histopatholgy
Adenocarcinomas  18  (52.9%)  
Squamous cell  carcinomas  9  (81.8%)  
Stage
I 12  (66.7%)  
II 7  (58.3%)  
III 8  (53.3%)  203
.1  years  for  EGFR  positive  patients  vs.  6  years  for  nega-
ive  p  <  0.712).  Median  survival  was  found  to  be  statistically
igniﬁcant  with  tumor  stage  (median  survival  9  years  in  stage
 tumors  and  2.5  years  in  stage  II  and  III  p  <  0.001)  (Table  4).
he  median  survival  was  6.2  years  for  adenocarcinomas  and
 years  for  squamous  cell  carcinomas  (p  =  0.854)  (Table  4).
No  correlation  between  the  expression  of  ERCC-1  and  the
egree  of  tumor  differentiation  was  made  due  to  the  fact
hat  diagnosis  was  made  from  small  tumor  FNA  samples  with
imited  quantity  of  tissue,  so  not  enough  to  make  conclusions
bout  differentiation  of  the  whole  tumor.
The  relationship  between  ERCC1  and  EGFR  expression
Negative  ERCC1  expression  was  signiﬁcantly  associated
ith  the  presence  of  EGFR  expression.  Of  18  patients
ith  negative  ERCC1  expression,  6  (33.3%)  had  an  EGFR
xpression  whereas  only  4  patients  (14.8%)  out  of  27
ith  positive  ERCC1  expression  had  an  EGFR  expression
p  =  0.015)  (Table  5).
iscussion
ung  cancer  continues  to  be  the  leading  cause  of  cancer
eath  worldwide.  The  prognosis  of  this  disease  remains
oor,  even  in  patients  with  NSCLCs  treated  by  surgical
esection,  because  undetectable  but  remaining  viable  tumor
ells  often  cause  local  and  distant  recurrences  after
nitial  treatment.  Postoperative  chemotherapy  has  been
ttempted  as  part  of  standard  therapy  to  improve  the
rognosis  in  patients  undergoing  surgery.  DNA  repair  pro-
eins,  including  ERCC-1  have  been  studied11 as  predictive11,12
actors  for  survival  in  patients  with  NSCLC.13--19 Epider-
al  growth  factor  receptor  (EGFR)  is  a  protein  tyrosine
inase  that  is  able  to  control  intracellular  pathways,  and  its
ctivation  promotes  tumor  proliferation,  angiogenesis  and
etastasis.20 EGFR  overexpression  as  detected  by  immuno-
istochemistry  has  been  observed  in  at  least  two  thirds  of
bles.
ssion  Total  P
(−)
12  (34.3%)  35  (100%)  0.083
6  (60%)  10  (100%)
9  (45%)  20  (100%)  0.245
9  (36%)  25  (100%)
10  (33.3%)  30  (100%)  0.029
8  (53.3%)  15  (100%)
16  (47.05%)  34  (100%)  <0.001
2  (18.18%)  11  (100%)
6  (33.3%)  18  (100%)  0.061
5  (41.7%)  12  (100%)
7  (46.7%)  15  (100%)
204  A.  Kalogeraki  et  al.
Table  3  Association  between  EGFR  expression  and  clinical  variables.
EGFR  expression  Total  P
(+)  (−)
Sex
Male  3  (8.6%)  32  (91.4%)  35  (100%)  0.001
Female 7  (70%)  3  (28.6%)  10  (100%)
Age
≤65 years  4  (20%)  16  (80%)  20  (100%)  0.340
>65 years 6  (24%)  19  (76%)  25  (100%)
Smoking status
Smokers  2  (6.6%) 28  (93.4%) 30  (100%) 0.001
Non Smokers  8  (53.3%)  7  (46.6%)  15  (100%)
Cyto-histology
Adenocarcinomas  10  (29.4%)  24  (70.6%)  34  (100%)
Stage
I 3  (16.6%)  15  (83.4%)  18  (100%)  0.583
II 3  (25%) 19  (75%)  12  (100%)
III 4  (26.6%) 11  (73.4%) 15  (100%)
NSCLC,  thus  paving  the  way  for  monoclonal  antibodies  such
as  cetuximab,  or  more  recently,  panitumumab  directed  at
the  extracellular  domain  of  EGFR,  to  prevent  ligand  bind-
ing  and  subsequent  receptor  activation  or  activate  immune
response  against  tumor  cells.20









≤65  20  5.5  0.669
>65 25  6.2
Sex
Male  35  5.7  0.810
Female  10  6.1
Smoking  status
Smokers  30  7.5  0.450
Non smokers  15  5.1
Tumor  stage
I 18  9  <0.001
II--III 27  2.9
Cyto-histopathology
Adenocarcinoma  34  6.2  0.854
Squamous  cell  carcinoma  11  6
ERCC-1  expression
Positive  27  7.5  0.045
Negative  18  3.8
EGFR  expression
Positive  10  5.1  0.712
Negative  35  6
EGFR  is  commonly  over  expressed  in  NSCLC  and  the
lack  of  consistent  methods  for  evaluating  its  expression  has
led  to  inconclusive  conclusions  about  EGFR  as  a  prognostic
factor.16
The  present  study  was  performed  for  ﬁrst  time  in
cytopathological  specimens(FNABs)  using  immunocytochem-
istry,  to  determine  if  ERCC1  and  EGFR  expressions  are
prognostic  markers  for  resected  NSCLC  in  patients  treated  in
a  single  institution.  Our  ﬁndings  indicate  that  patients  with
ERCC-1  positive  tumors  survived  signiﬁcantly  longer  after
surgery  than  those  with  ERCC1  negative  tumors  (Table  4),
which  is  in  accordance  with  the  ﬁndings  of  other  recent
studies11,14,18 but  not  in  agreement  with  others12,13,15,16 that
indicate  a  better  outcome  in  patients  with  low  expression
levels  of  ERCC1.
ERCC1  expression  was  identiﬁed  as  positive  (scores  2+  and
3+)  in  the  majority  of  NSCLCs  and  seems  to  be  an  indepen-
dent  prognostic  marker  of  longer  survival.  In  addition  EGFR
expression  was  positive  (scores  2+  and  3+)  in  the  minority
of  NSCLCs  and  only  in  adenocarcinomas,  more  frequently  in
ERCC1-negative  (scores  0  and  1+)  tumors,  suggesting  that  it
is  not  an  independent  prognostic  marker  for  the  outcome  of
the  patients  suffering  from  NSCLC.
In  our  study  EGFR  expression  was  more  commonly  found
in  tumors  not  expressing  ERCC1  (Table  5).  The  relationship
between  EGFR  mutations  and  ERCC1  expression  has  not
been  investigated  in  patients  with  NSCLC11 although  there
is  a  report  which  found  no  correlation  between  ERCC-1  and
Table  5  Relationship  between  ERCC1  and  EGFR  expression.
EGFR  Total  P
(+)  (−)
ERCC1  (−)  6  (33.3%)  12  (66.6%)  18  (100%)  0.015























































samples.24,25ERCC-1,  EGFR,  and  clinical  variables  in  NSCLC  
EGFR  mRNA  expression.16 One  possible  explanation  is  that
the  pathogenesis  of  ERCC1  positive  tumors  differs  from
that  of  EGFR  mutant  tumors  as  depicted  by  the  ‘‘oncogene
addiction’’  theory.  In  this  study  ERCC1  expression  was  more
frequent  in  squamous  cell  carcinomas  and  in  smokers  and
EGFR  expression  only  in  adenocarcinomas  and  was  more  fre-
quent  in  women  and  non  smokers  (Tables  2  and  3),  this  may
be  due  to  the  infrequency  of  EGFR  mutation  in  these  patient
groups.19 Simon  et  al.  conclude  that  resected  NSCLC  patients
with  high  ERCC-1  expression  (>50)  have  a  better  survival  rate
compared  to  patients  with  low  ERCC-1  expression  (<50).21
Current  data  suggest  that  ERCC1  is  a  potentially  use-
ful  marker  for  predicting  clinical  resistance  to  platinum
compounds  such  as  cisplatin,  carboplatin  and  oxaliplatin.
However,  no  study  has  yet  provided  sufﬁciently  robust  evi-
dence  to  consider  ERCC1  as  a  marker  for  resistance  to  all
types  of  chemotherapy.  Before  the  potential  of  ERCC1  as  a
predictor  of  chemosensitivity  can  be  fully  evaluated,  sev-
eral  technical  and  practical  obstacles  should  be  addressed.
First,  the  diagnosis  is  made  from  small  tumor  samples
(biopsies)  with  limited  quantity  of  bronchial  tissue.  Since
ERCC1  immunostaining  is  characterized  by  heterogeneity,
suboptimal  sampling  might  mean  that  the  biopsy  is  not  nec-
essarily  representative  of  the  whole  tumor.  Furthermore,
tumor  material  could  be  obtained  either  from  the  primary
or  the  metastatic  sites.  This  may  be  signiﬁcant  since  it
has  not  been  shown  that  ERCC1  expression  is  identical  in
the  primary  tumor  and  its  metastatic  locations.  Secondly,
studies  associating  ERCC1  with  resistance  to  platinum  com-
pounds  have  so  far  been  conducted  mainly  by  DNA  or  RNA
molecular  analysis,  which  is  both  technically  demanding  and
expensive.  The  IALT  (International  Adjuvant  Lung  Cancer
Trial)-bio  study  had  the  advantage  of  using  immunohisto-
chemistry  to  assess  ERCC1  expression,  which  is  a  feasible
technique  in  the  everyday  practice  of  a  pathology
laboratory.  Should  the  technical  aspects  of  ERCC1  immuno-
histochemistry  become  standardized  and  optimized,  this
methodology  could  rapidly  be  translated  into  a  clinical
reality  after  other  conﬁrmatory  prospective  studies.  Cur-
rently,  however,  difﬁculties,  including  the  identiﬁcation  of
an  optimal  ‘‘cut-off’’  value  for  ERCC1,  the  subjectivity
of  the  pathological  examination,  particularly  in  prospec-
tive  studies,  and  the  heterogeneity  of  staining,  that  makes
the  technique  of  tissue  micro-arrays  not  really  applica-
ble,  limit  the  clinical  usefulness  of  such  procedures.  Other
difﬁculties,  such  as  different  genetic  backgrounds  in  the
population,  or  interaction  with  smoking  habits,  should  be
further  discussed.  In  any  case,  meticulous  methodological
considerations  and  standardization  are  mandatory.  It  is  nec-
essary  that  future  larger  and  prospective  studies  should  be
extensively  discussed  within  multidisciplinary  groups  includ-
ing  highly  skilled  pathologists  and  bio-statisticians.22
In  conclusion,  we  were  able  to  use  cytological  speci-
mens  (FNABs)  to  study  the  expressions  of  ERCC1  and  EGFR
and  their  role  in  patients  with  NSCLC.  ERCC1  expression
as  determined  immunocytochemically,  was  identiﬁed  as  a
prognostic  marker  of  longer  survival  in  NSCLCs.  In  addition,
EGFR  expression  was  more  frequently  found  in  ERCC-1  nega-
tive  tumors,  but  did  not  affect  survival  in  the  present  study.
Perhaps  more  studies  for  the  status  of  the  genes  and  fur-
ther  validation  of  the  correlation  between  ERCC1  and  EGFR
expressions  in  longer  number  of  patients  are  warranted.
f
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National  Comprehensive  Cancer  Network  (NCCN)  --  The
CCN’s  clinical  practice  guidelines  regarding  NSCLC  includes
nformation  about  the  role  of  ERCC1  as  both  a  prognostic  and
redictive  biomarker  for  NSCLC.  However,  the  guidelines  do
ot  include  recommendations  about  the  use  of  ERCC1  testing
n  NSCLC  patients.23
Test  accuracy  and  reliability  in  measuring  ERCC1  expres-
ion  (analytic  sensitivity  and  speciﬁcity).
ERCC1  testing  is  performed  by  IHC  using  an  antibody  to
etect  the  ERCC1  protein.  Two  studies  evaluated  the  speci-
city  of  the  8F1  ERCC1  antibody  and  yielded  conﬂicting
esults:  Niedernhofer  and  colleagues  (2007)  compared  the
erformance  of  8F1  with  that  of  a  second  commercially
vailable  antibody,  FL-297.  Test  samples  included  normal
uman  ﬁbroblasts  (positive  control)  and  cells  from  patients
ith  inherited  sequence  variants  in  the  ERCC1  and  xero-
erma  pigmentosum  complementation  group  F (XPF)  genes.
sing  the  FL-297  antibody,  immunoblotting  of  cell  lysates
evealed  a  single  band  of  the  expected  molecular  weight  in
ormal  ﬁbroblasts,  but  reduced  levels  of  the  protein  in  the
atient  cells.  Using  the  8F1  antibody,  however,  immunoblot-
ing  of  cell  lysates  from  normal  ﬁbroblasts  revealed  two
eparate  bands:  a  band  of  unknown  origin  and  a  band  cor-
esponding  to  the  ERCC1  protein.  In  the  patient  cell  lines,
nly  a single  band  was  seen,  which  the  authors  state  rep-
esented  a  protein  of  unknown  origin  that  is  cross-reacting
o  the  8F1  antibody.  In  a  second  experiment,  normal  ﬁbro-
lasts  and  cells  from  the  patient  with  an  XPF  gene  variant
ere  differentially  labeled  and  co-cultured.  Immunostaining
evealed  that  the  FL-297  antibody  was  reactive  in  the  normal
broblasts,  but  not  in  the  cells  from  the  patient.  In  con-
rast,  the  8F1  antibody  yielded  nuclear  staining  in  all  cells.
mmunostaining  of  cells  from  the  patient  with  an  ERCC1
ene  variant  was  not  reported.  The  authors  concluded  that
hese  results  suggest  that  the  8F1  antibody  is  not  speciﬁc
or  the  ERCC1  protein  and  cannot  discriminate  between
RCC1-positive  and  ERCC1-deﬁcient  cells.  Data  conﬁrming
ecreased  expression  of  ERCC1  in  the  patient  cell  lines  were
ot  included  in  this  study.24
Olaussen  et  al.25 further  studied  the  speciﬁcity  of  the
F1  antibody  in  response  to  the  claim  by  Niedernhofer
nd  colleagues  (2007)  that  this  antibody  may  not  be  spe-
iﬁc  for  ERCC1.  Several  complementary  approaches  using
mall  interfering  RNAs  (siRNAs)  were  utilized.  First,  siRNAs
esigned  to  block  ERCC1  expression  were  used  to  deplete
wo  epithelial  carcinoma  cell  lines  (including  one  NSCLC  cell
ine)  of  ERCC1  protein.  Using  the  8F1  antibody,  immunoblot-
ing  detected  a  single  band  of  the  expected  molecular
eight  in  each  cell  line.  After  treatment  with  the  siRNA,
his  band  disappeared.  In  a  second  experiment,  cell  pellets
rom  treated  and  untreated  cell  lines  were  ﬁxed  and  embed-
ed  using  the  same  methods  used  for  resected  lung  tumors.
ubsequently,  IHC  was  performed  using  the  8F1  antibody.
uclear  ERCC1  staining  was  clearly  evident  in  the  untreated
ontrol  cells;  however,  this  staining  was  absent  in  cells  that
ere  transfected  with  the  siRNA.  The  authors  concluded
hat  these  results  suggest  that  8F1  is  speciﬁc  when  used
or  the  immunohistochemical  detection  of  ERCC1  in  NSCLCTwo  studies  evaluated  the  importance  of  specimen  type
or  ERCC1  expression  testing:  Taillade  and  colleagues26 eval-






























































ther  biomarkers  for  NSCLC)  in  both  bronchial  biopsies  and
urgical  specimens  (i.e.,  resected  tumors)  in  34  patients.
he  8F1  antibody  was  used  for  IHC  and  two  separate
athologists  scored  each  sample  blindly.  Results  were
ichotomized  into  negative  and  positive  based  on  a  cutoff  of
0%  ERCC1  antibody  reactivity  within  tumor  cells  (i.e.,  a  pos-
tive  result  indicated  that  at  least  10%  of  cells  demonstrated
 reactivity  to  the  ERCC1  antibody).  Seven  samples  were
ound  to  lack  a  valid  internal  control  and  were  excluded
rom  the  analysis.  The  discordance  in  scoring  between  the
wo  pathologists  (indicated  by  a  discrepancy  >20%  in  stain-
ng  percentage)  was  7%.  Overall,  when  comparing  the  results
btained  from  biopsies  and  surgical  specimens,  a  statisti-
ally  signiﬁcant  correlation  was  found  (correlation  coefﬁ-
ient  r  =  0.83;  P  <  0.0001).  With  the  cutoff  of  10%,  8  (30%)
iopsies  and  11  (41%)  resected  tumors  were  found  to  be  pos-
tive  for  ERCC1.  Thus,  the  discordance  between  specimen
ypes,  when  examining  positive  versus  negative  results,  was
%  (95%  conﬁdence  interval  [CI],  0%  to  18.4%).  The  authors
oncluded  the  above  results  suggest  that,  while  there  is  a
trong  correlation  between  ERCC1  levels  in  bronchial  biop-
ies  and  resected  tumor  specimens,  discordance  is  evident
or  different  specimen  types  in  some  cases.26
Gomez-Roca  and  colleagues27 assessed  the  levels  of
RCC1  in  primary  NSCLC  tumor  specimens  compared  with
he  levels  found  in  corresponding  metastases.  IHC  using  the
F1  antibody  was  performed  in  49  NSCLC  patients  who  had
oth  types  of  test  specimens  available.  Using  an  H  score
semiquantitative  scores  calculated  by  summing  the  prod-
cts  of  staining  intensities  and  distributions)  of  1  to  classify
he  ERCC1  expression,  18  primary  tumors  and  26  metastatic
esions  were  found  to  be  ERCC1  positive.  However,  there  was
 signiﬁcantly  higher  level  of  ERCC1  expression  in  metastases
han  in  primary  tumors  (P  =  0.04).  ERCC1  expression  was
t  least  ﬁve  times  greater  in  metastatic  lesions  (especially
rain  metastases)  than  in  corresponding  tumors.  ERCC1  sta-
us  was  discordant  in  20  of  the  49  (41%)  patients.  The  authors
oncluded  that  these  results  suggest  that  it  may  be  appro-
riate  to  examine  ERCC1  levels  in  both  primary  tumors
nd  metastatic  lesions  prior  to  deciding  on  a  treatment
egimen.27
The  body  of  evidence  surrounding  ERCC1  testing  in  NSCLC
ndicates  that  the  analytical  validity  of  ERCC1  testing  using
HC  may  have  limitations.  Conﬁrmatory  prospective  studies,
ith  several  centers  and  countries  will  be  needed.
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